Sandra Tuyaerts
Brussels, BRU, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 44 publications
Reinvigorating the Cancer-Immunity Cycle by Intratumoral Administration of Conventional Dendritic Cells in Melanoma and Other Solid Tumors: A Narrative Review.
Journal: Vaccines
Published: March 30, 2026
Circulating immune cell profiling in advanced cervical and endometrial cancer patients treated with PD-1 blockade, radiotherapy, and immune modulation in the PRIMMO trial.
Journal: Frontiers in immunology
Published: January 22, 2026
Efficacy and safety of regorafenib in patients with advanced pretreated melanoma: results of the RegoMel phase II clinical trial.
Journal: ESMO open
Published: January 09, 2026
Oncolytic HSV-1 expressing FLT3L kills melanoma, glioblastoma, and pancreatic cancer cells in vitro and induces immunogenic cell death.
Journal: Molecular therapy. Oncology
Published: February 07, 2025
Correction: Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study.
Journal: Cancer immunology, immunotherapy : CII
Published: December 31, 2024
Preclinical evaluation of antigen-sensitive B7-H3-targeting nanobody-based CAR-T cells in glioblastoma cautions for on-target, off-tumor toxicity.
Journal: Journal for immunotherapy of cancer
Published: October 27, 2024
Intracranial administration of anti-PD-1 and anti-CTLA-4 immune checkpoint-blocking monoclonal antibodies in patients with recurrent high-grade glioma.
Journal: Neuro-oncology
Published: October 15, 2024
Associations of the gut microbiome with outcomes in cervical and endometrial cancer patients treated with pembrolizumab: Insights from the phase II PRIMMO trial.
Journal: Gynecologic oncology
Published: August 09, 2024
An open-label, single-arm, prospective, multi-center, tandem two-stage designed phase II study to evaluate the efficacy of fulvestrant in women with recurrent/metastatic estrogen receptor-positive gynecological malignancies (FUCHSia study).
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: May 09, 2024
A randomized phase II clinical trial of stereotactic body radiation therapy (SBRT) and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells in solid tumors.
Journal: Cancer immunology, immunotherapy : CII
Published: March 15, 2024
Intratumoral administration of the immunologic adjuvant AS01B in combination with autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma.
Journal: Journal for immunotherapy of cancer
Published: December 13, 2023
PI3K/mTOR inhibition induces tumour microenvironment remodelling and sensitises pS6high uterine leiomyosarcoma to PD-1 blockade.
Journal: Clinical and translational medicine
Published: October 16, 2023
Last Updated: 09/26/2026